Representative Matters

Commercial and Real Estate Litigation

• Currently represent the developer of mixed-use condominium complexes in related actions against the general contractor, alleging construction defect and various tort claims.
• Obtained a preliminary injunction on behalf of publicly traded transportation and logistics conglomerate in civil litigation involving trade secret misappropriation claims.
• Obtained full dismissal of breach of contract and civil trespass claims brought against a publicly traded telecommunications service provider arising from the alleged misplacement of certain underground fiber optic cables. Live Work Play Developers, LLC v. AT&T Corp. (Fla. Cir. Ct. 2019).

Regulatory/Administrative

• Represented The Benchmark Company LLC, acting as underwriter in a $12.5 million offering of preferred stock for Fortress Biotech, Inc. (Nasdaq: FBIOP), a developer of pharmaceutical and biotechnology products and product candidates.

• Represented B. Riley FBR, Inc., acting as sales agent in a $150 million at the market equity offering of common stock for Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases, including a potential COVID-related vaccine.

• Represented JMP Securities LLC and Oppenheimer & Co., acting as underwriters in a $25 million public offering of common stock and related warrants for Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company primarily focused on developing and commercializing innovative products for acute care settings.

• Represented JMP Securities LLC, acting as sales agent in a $25 million at the market equity offering of common stock for iCAD, Inc. (Nasdaq: ICAD), a global medical technology company that provides innovative cancer detection and therapy solutions.

• Represent pharmacy operator in connection with civil administrative enforcement action brought by the DEA.

Cannabis

• Cannabis regulatory counsel to a venture capital firm focused on acquiring and developing businesses specializing in cannabis-related consumer goods.
• Regulatory counsel to an aromatherapy and essential oils products manufacturer in connection with the company’s entry into the hemp-derived CBD market.
• Cannabis regulatory counsel to multi-state medical marijuana operator.
• Provided state-specific regulatory advice on the cultivation, manufacture, and sale of CBD products to publicly traded international cannabinoid company.
• Advised a private credit asset management firm on cannabis-related regulatory matters in connection with its provision of a revolving credit facility to support the capital needs of a publicly traded supplier to businesses in the cannabis industry.

Admissions

• Florida
• U.S. District Court for the Southern District of Florida
• U.S. District Court for the Middle District of Florida
• U.S. District Court for the Northern District of Florida

Education

• University of Miami School of Law, J.D., summa cum laude, 2018
  - Order of the Coif
  - Online Editor, University of Miami Law Review
• Columbia University, B.A., magna cum laude, 2014
  - Phi Beta Kappa

Experience

• Duane Morris LLP
  - Associate, 2018-present

Civic and Charitable Activities

• Big Brothers Big Sisters of Palm Beach and Martin Counties

Professional Activities

• Federal Bar Association, 2019-present

• Food and Drug Law Institute (FDLI), 2019-present
  - Cannabis-Derived Products Committee

Selected Publications

• Co-author, "Consumer Class Actions Against CBD Companies Are Hitting a Snag," Cannabis Industry Journal, August 25, 2020
• Co-author, "Okla. High Court Marijuana Ruling Provides Preemption Guide," Law360, July 1, 2020
• Co-author, "Preparing for Resource-Draining Lawsuits," mg Magazine, April 2020
• Co-author, "A Cannabidiol Catalyst? Recent Events Increase Pressure on FDA to Regulate CBD," FDLI Update, Spring 2020
• Co-author, "Why Reformers Want Disclosure Of 3rd-Party MDL Funding," Law360, January 13, 2020
• Co-author, "THC Vaping Health Issues Warrant Safety Standards," Law360, September 25, 2019

• Co-author, "Florida’s Budding Cannabis Industry Expands With New Hemp Law," Daily Business Review, July 1, 2019

• Co-author, “International E-Discovery: How The 11th Circuit’s Interpretation of ‘Possession, Custody, or Control’ May Impact Multinational Corporations,” The Florida Bar Journal, January/February 2019

Duane Morris Alerts

• Co-author, "D.C. Circuit Rules That FDA Lacks Authority to Regulate a Product as a Drug When It Also Satisfies Statutory Definition of a Device," Duane Morris Alert, April 26, 2021
• Co-author, "New FDA Guidance Embraces "Remote Interactive Evaluations" but Stops Short of Permitting Virtual 704(a) Inspections," Duane Morris Alert, April 19, 2021
• Co-author, "Florida Adopts New COVID-19 Civil Liability Limitations," Duane Morris Alert, April 5, 2021
• Co-author, "Florida Legislators Introduce Bills That Would Impose Strict Prerequisites to Bringing COVID-19 Personal Injury Claims," Duane Morris Alert, January 11, 2021
• Co-author, "Florida Industry Group Urges State to Limit Legal Liability for Florida Businesses," Duane Morris Alert, December 4, 2020
• Co-author, "FDA Clarifies Types of Evidence It Will Consider When Determining a Medical Product's 'Intended Use'," Duane Morris Alert, October 6, 2020
• Co-author, "New MAPP Explains Process for Changing Ownership of Generic Drug Applications," Duane Morris Alert, September 8, 2020
• Co-author, "New Guidance Reveals FDA's Thinking on Imposition of Civil Monetary Penalties for Violations of Clinical Trial Reporting Requirements," Duane Morris Alert, August 27, 2020
• Co-author, "DEA Issues Interim Final Rule Concerning Marijuana and Hemp," Duane Morris Alert, August 24, 2020
• Co-author, "FDA Clarifies Policy on Scope of Review of Multiple-Function Device Products," Duane Morris Alert, August 6, 2020
• Co-author, "New FDA Draft Guidance on Cannabis-Related Clinical Research Omits Discussion of Nondrug CBD Products," Duane Morris Alert, July 23, 2020
• Co-author, "FDA Issues Guidance on Procedures for Device Establishment Inspections," Duane Morris Alert, July 8, 2020
• Co-author, "As COVID-19 Cases Mount, South Florida Counties Reimpose Restrictions Before Holiday Weekend," Duane Morris Alert, July 1, 2020
• Co-author, "Amid National Outcry for Police Accountability, Supreme Court Declines to Review Qualified Immunity," Duane Morris Alert, June 15, 2020
• Co-author, "New FDA Compliance Program Details FDA Expectations for Inspections of CDER- or CDRH-Led Combination Product Manufacturers," Duane Morris Alert, June 12, 2020
• Co-author, "Judicial Decisions Reflect Need for CBD Regulations and Legal Counsel," Duane Morris Alert, June 9, 2020
• Co-author, "Florida Initiates Phase 1 of Reopening, with South Florida Counties Following a Different Track," Duane Morris Alert, May 4, 2020
• Co-author, "FDA Takes Steps to Enhance Availability of Safe and Effective Face Masks," Duane Morris Alert, April 22, 2020
• Co-author, "CARES Act Expands Immunity Protections for Covered Countermeasures and Healthcare Volunteers," Duane Morris Alert, April 13, 2020

  CARES Act Expands Immunity Protections for Covered Countermeasures and Healthcare Volunteers
• Co-author, "CARES Act Package Ushers in Changes to OTC Drug Review Process," Duane Morris Alert, April 13, 2020
• Co-author, "Florida Governor Clarifies Terms of First Statewide Safer-at-Home Order," Duane Morris Alert, April 6, 2020
• Co-author, "Florida Governor Issues Statewide Order Restricting Activities Outside the Home," Duane Morris Alert, April 2, 2020
• Co-author, "FDA Unveils Program to Expedite Coronavirus Treatments," Duane Morris Alert, April 1, 2020
• Co-author, "Florida Governor Issues Stay-at-Home Order—But Only for Southeast Florida," Duane Morris Alert, March 31, 2020
• Co-author, "Mix of Statewide Emergency Rules and Local Advisories Dominate Florida's Reaction to COVID-19," Duane Morris Alert, March 24, 2020
• Co-author, "Declaration Provides Immunity for Certain COVID-19 Pandemic Medical Countermeasure Activities," Duane Morris Alert, March 18, 2020
• Co-author, "FDA Guidance Aims to Accelerate Availability of COVID-19 Tests," Duane Morris Alerts, March 18, 2020
• Co-author, "FDA's Report on CBD Reaffirms Status Quo," Duane Morris Alert, March 13, 2020
• Co-author, "FDA Postpones Foreign Inspections Through April in Response to COVID-19," Duane Morris Alert, March 12, 2020
• Co-author, "FDA Revises Policies and Procedures for Prioritization of ANDAs," Duane Morris Alert, February 6, 2020
• Co-author, "FDA Provides Insight on Research and Drug Approval for Cannabis Products," Duane Morris Alert, January 24, 2020
• Co-author, "Federal Minimum Age for Purchase of Tobacco Products Including E-Cigarettes Raised from 18 to 21," Duane Morris Alert, December 24, 2019
• Co-author, "With a Flurry of Warning Letters and a Consumer Update, FDA Signals Commitment to CBD Enforcement Policy," Duane Morris Alert, December 2, 2019 
• Co-author, "FDA's Bark May Be Worse Than Its Bite: Revised Guidance Permits Certain Compounding of Animal Drugs from Bulk Drug Substances," Duane Morris Alert, November 25, 2019
• Co-author, "U.S. Senators Urge Changes to Testing Requirements Under USDA Interim Final Rule for Hemp Program," Duane Morris Alert, November 22, 2019 
• Co-author, "In a Regulatory 'One-Two,' FDA Modifies Terms of Oversight Concerning Homeopathic Drugs," Duane Morris Alert, October 31, 2019
• Co-author, "USDA Releases Long-Awaited Federal Rules on Hemp Production, but State-by-State Regulatory Differences Remain," Duane Morris Alert, October 30, 2019
• Co-author, "In Cannabis Case, Tax Court Dissent Concludes Section 280E Is Unconstitutional," Duane Morris Alert, October 24, 2019
• Co-author, "Federal Agencies Issue Draft Guidance for Drug Master Files for First Time in 30 Years," Duane Morris Alert, October 22, 2019
• Co-author, "Discovery Ruling in District of Minnesota May Have Far-Reaching Implications for FCA Defendants," Duane Morris Alert, October 8, 2019

• Co-author, "FTC Warning Letters and Reports of Vaping-Related Illnesses Hit Cannabis Industry," Duane Morris Alert, September 11, 2019

• Co-author, "Much of Oklahoma's $572 Million Opioid Case Likely to Be Replicated Elsewhere, But Unique Cause of Action May Not," Duane Morris Alert, August 28, 2019

• Co-author, "OTC Personal Products Manufacturer Cited by FDA for Various Regulatory Violations," Duane Morris Alert, August 27, 2019

• Co-author, "New Texas Law Advances Hemp Production and Regulation," Duane Morris Alert, June 12, 2019

• Co-author, "USDA Provides Memo Clarifying Key Provisions of 2018 Farm Bill Regarding Hemp," Duane Morris Alert, May 30, 2019

• Co-author, "A Green Light for the Sunshine State - Florida Legislature Approves Sweeping Changes to Hemp, CBD Regulation," Duane Morris Alert, May 7, 2019

Selected Speaking Engagements

• Presenter, "Virtual Happy Hour with Update Magazine Authors Rick Ball and Justin Stern," Food and Drug Law Institute, April 30, 2020
• Presenter, "Cannabis 303: Civil Litigation and COVID-19 Implications for the Cannabis Industry: An Unavoidable Consequence of a Maturing U.S. Cannabis Market," Duane Morris Cannabis Webinar Series, April 21, 2020

  Civil Litigation and COVID-19 Implications for the Cannabis Industry: An Unavoidable Consequence of a Maturing U.S. Cannabis Market

• Speaker, "Risks Associated With Cannabis Banking," South Florida Compliance Association, February 11, 2020
• Speaker, "Cannabis Issues in Commercial Real Estate," 6th Annual NAI Florida & Caribbean Conference, Intercontinental Miami, Miami, Florida, November 14-15, 2019
• Speaker, "Overview of New Federal Rules on Hemp Production and Q&A," Duane Morris and American Trade Association for Cannabis and Hemp, Webinar, November 6, 2019

• Presenter, "Cannabis 204: The Roundup of State Cannabis Legislation," Duane Morris Cannabis Webinar Series, August 20, 2019

• Presenter, "Possession, Custody, or Control Under Fed. R. Civ. P. 34: Implications of Interpretation," Miami, FL, April 12, 2019